AE Wealth Management LLC Acquires 3,213 Shares of Bristol-Myers Squibb Co (BMY)
AE Wealth Management LLC increased its holdings in Bristol-Myers Squibb Co (NYSE:BMY) by 11.3% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 31,581 shares of the biopharmaceutical company’s stock after purchasing an additional 3,213 shares during the period. AE Wealth Management LLC’s holdings in Bristol-Myers Squibb were worth $1,642,000 at the end of the most recent reporting period.
Other large investors have also modified their holdings of the company. Trust Co. of Virginia VA boosted its holdings in Bristol-Myers Squibb by 105.7% in the fourth quarter. Trust Co. of Virginia VA now owns 50,048 shares of the biopharmaceutical company’s stock worth $2,601,000 after purchasing an additional 25,712 shares in the last quarter. Chescapmanager LLC boosted its holdings in Bristol-Myers Squibb by 22.1% in the fourth quarter. Chescapmanager LLC now owns 361,755 shares of the biopharmaceutical company’s stock worth $18,804,000 after purchasing an additional 65,367 shares in the last quarter. ERTS Wealth Advisors LLC bought a new stake in Bristol-Myers Squibb in the fourth quarter worth $289,000. Savant Capital LLC lifted its position in Bristol-Myers Squibb by 7.3% during the 4th quarter. Savant Capital LLC now owns 11,523 shares of the biopharmaceutical company’s stock worth $599,000 after acquiring an additional 781 shares during the last quarter. Finally, Symons Capital Management Inc. acquired a new position in Bristol-Myers Squibb during the 4th quarter worth $5,603,000. Hedge funds and other institutional investors own 74.27% of the company’s stock.
A number of research analysts have weighed in on the stock. Credit Suisse Group reissued a “hold” rating and set a $59.00 target price on shares of Bristol-Myers Squibb in a research report on Thursday, December 13th. Zacks Investment Research raised shares of Bristol-Myers Squibb from a “hold” rating to a “buy” rating and set a $60.00 target price for the company in a research report on Tuesday, March 5th. BMO Capital Markets reissued a “buy” rating and set a $60.00 target price on shares of Bristol-Myers Squibb in a research report on Thursday, January 3rd. Bank of America cut their target price on shares of Bristol-Myers Squibb from $53.00 to $51.00 and set a “neutral” rating for the company in a research report on Tuesday, February 19th. Finally, Morgan Stanley set a $54.00 target price on shares of Bristol-Myers Squibb and gave the stock a “hold” rating in a research report on Thursday, December 20th. One research analyst has rated the stock with a sell rating, twelve have assigned a hold rating and six have given a buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average price target of $59.13.
Bristol-Myers Squibb (NYSE:BMY) last announced its quarterly earnings data on Thursday, January 24th. The biopharmaceutical company reported $0.94 EPS for the quarter, beating the Zacks’ consensus estimate of $0.85 by $0.09. The business had revenue of $5.97 billion during the quarter, compared to analyst estimates of $5.95 billion. Bristol-Myers Squibb had a net margin of 21.95% and a return on equity of 48.99%. The firm’s revenue for the quarter was up 9.6% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.68 earnings per share. Equities analysts predict that Bristol-Myers Squibb Co will post 4.15 EPS for the current year.
The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, May 1st. Stockholders of record on Friday, April 5th will be given a dividend of $0.41 per share. This represents a $1.64 dividend on an annualized basis and a dividend yield of 3.57%. The ex-dividend date of this dividend is Thursday, April 4th. Bristol-Myers Squibb’s dividend payout ratio is currently 41.21%.
About Bristol-Myers Squibb
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers drugs in oncology, immunoscience, cardiovascular, and fibrotic diseases. The company's products include Opdivo, a biological product for anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in adult patients with non-valvular atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders; and Orencia, a biological product for adult patients with moderately to severely active RA and prostate-specific antigen, as well as reducing signs and symptoms in certain pediatric patients with moderately to severely active polyarticular juvenile idiopathic arthritis.
Featured Article: Diluted Earnings Per Share
Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Co (NYSE:BMY).
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.